NVP 1402

Drug Profile

NVP 1402

Alternative Names: NVP1402

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Navipharm
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I CNS disorders

Most Recent Events

  • 02 May 2018 Navipharm Corporation completes a phase I pharmacokinetic trial in healthy volunteers in South Korea (NCT03340480)
  • 12 Dec 2017 Navipharm Corporation initiates enrolment in a phase I pharmacokinetic trial in healthy volunteers in South Korea (NCT03340480)
  • 20 Nov 2017 Navipharm plans a phase I trial in healthy volunteers in December 2017 (NCT03340480)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top